Balyasny Asset Management LLC Mirati Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $31.7 Million - $47.1 Million	-755,826 Reduced 97.43%	19,921 $1.17 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $21.6 Million - $35.2 Million	775,747 New	775,747 $33.8 Million
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $554,786 - $823,829	15,183 Added 33.34%	60,724 $2.26 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $1.88 Million - $4.49 Million	45,541 New	45,541 $2.06 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $12.3 Million - $17.2 Million	-77,464 Closed	0 $0

Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $12.6 Million - $18.6 Million	77,464 New	77,464 $17 Million
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $324,128 - $539,795	-4,645 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $328,680 - $598,554	4,645 New	4,645 $599,000
Q1 2019 May 15, 2019	SELL	$43.65 - $78.95 $3.28 Million - $5.93 Million	-75,166 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$32.0 - $47.43 $781,888 - $1.16 Million	24,434 Added 48.16%	75,166 $3.19 Million
Q3 2018 Nov 14, 2018	BUY	$47.1 - $62.7 $2.39 Million - $3.18 Million	50,732 New	50,732 $2.39 Million
Q1 2018 May 15, 2018	SELL	$17.2 - $34.95 $211,560 - $429,885	-12,300 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$12.65 - $19.0 $117,645 - $176,700	-9,300 Reduced 43.06%	12,300 $224,000
Q3 2017 Nov 14, 2017	BUY	$4.7 - $11.7 $101,520 - $252,719	21,600	21,600 $253,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.